The trajectory of Sildenafil presents a challenging picture for shareholders. While the initial release generated substantial gains, the lapse of its intellectual property protection opened the floodgates to generic https://bookmarkcolumn.com/story21430218/the-copyright-and-pharma-a-precarious-opportunity